Your browser doesn't support javascript.
loading
Higher Delta variant-specific neutralizing antibodies prevented infection in close contacts vaccinated with ancestral mRNA vaccines during the SARS-CoV-2 Delta wave.
Goh, Yun Shan; Fong, Siew-Wai; Tay, Matthew Zirui; Rouers, Angeline; Chang, Zi Wei; Chavatte, Jean-Marc; Hor, Pei Xiang; Loh, Chiew Yee; Huang, Yuling; Tan, Yong Jie; Wang, Bei; Ngoh, Eve Zi Xian; Mohd Salleh, Siti Nazihah; Lee, Raphael Tze Chuen; Lim, Georgina; Maurer-Stroh, Sebastian; Wang, Cheng-I; Leo, Yee-Sin; Lin, Raymond T P; Lam, Meng Chon; Lye, David C; Young, Barnaby Edward; Ng, Lisa F P; Renia, Laurent.
Affiliation
  • Goh YS; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos #05-13, Singapore, 138648, Singapore.
  • Fong SW; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos #05-13, Singapore, 138648, Singapore.
  • Tay MZ; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos #05-13, Singapore, 138648, Singapore.
  • Rouers A; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos #05-13, Singapore, 138648, Singapore.
  • Chang ZW; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos #05-13, Singapore, 138648, Singapore.
  • Chavatte JM; National Public Health Laboratory, National Centre for Infectious Diseases, Singapore, Singapore.
  • Hor PX; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos #05-13, Singapore, 138648, Singapore.
  • Loh CY; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos #05-13, Singapore, 138648, Singapore.
  • Huang Y; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos #05-13, Singapore, 138648, Singapore.
  • Tan YJ; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos #05-13, Singapore, 138648, Singapore.
  • Wang B; Singapore Immunology Network, A*STAR, Singapore, Singapore.
  • Ngoh EZX; Singapore Immunology Network, A*STAR, Singapore, Singapore.
  • Mohd Salleh SN; Singapore Immunology Network, A*STAR, Singapore, Singapore.
  • Lee RTC; Bioinformatics Institute, A*STAR, Singapore, Singapore.
  • Lim G; GISAID Global Data Science Initiative (GISAID), Munich, Germany.
  • Wang CI; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos #05-13, Singapore, 138648, Singapore.
  • Leo YS; National Public Health Laboratory, National Centre for Infectious Diseases, Singapore, Singapore.
  • Lin RTP; Bioinformatics Institute, A*STAR, Singapore, Singapore.
  • Lam MC; GISAID Global Data Science Initiative (GISAID), Munich, Germany.
  • Lye DC; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Young BE; Department of Biological Sciences, National University of Singapore, Singapore, Singapore.
  • Ng LFP; Singapore Immunology Network, A*STAR, Singapore, Singapore.
  • Renia L; National Centre for Infectious Diseases (NCID), Singapore, Singapore.
Sci Rep ; 13(1): 19331, 2023 11 07.
Article in En | MEDLINE | ID: mdl-37935965
ABSTRACT
Identification of the risk factors and the high-risk groups which are most vulnerable is critical in COVID-19 disease management at a population level. Evaluating the efficacy of vaccination against infections is necessary to determine booster vaccination strategies for better protection in high-risk groups. In this study, we recruited 158 mRNA-vaccinated individuals during the Delta wave of SARS-CoV-2 infections in Singapore and examined the antibody profiles of infected individuals. We found that, despite high exposure due to communal living conditions in proximity, 4% of individuals (6/158) had PCR-confirmed infections and 96% (152/158) remained uninfected. Time-course analysis of the antibody profile at the start and the end of quarantine period showed Delta-specific boosting of anti-spike antibody response in 57% of the uninfected individuals (86/152). In the remaining 43% of the uninfected individuals (66/152) with no Delta-specific antibody boost, we found a higher Delta-specific antibody response at the start of quarantine period, which correlated with higher Delta pseudovirus neutralizing capacity. Our findings indicate that a higher basal variant-specific antibody response in the mRNA-vaccinated individuals contributes to better protection against infections by the new emerging SARS-CoV-2 variants.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Neutralizing / COVID-19 Limits: Humans Language: En Journal: Sci Rep Year: 2023 Type: Article Affiliation country: Singapore

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Neutralizing / COVID-19 Limits: Humans Language: En Journal: Sci Rep Year: 2023 Type: Article Affiliation country: Singapore